Piperacillin Sodium Clinical Trials

Size	Price	Qty
50mg	USD 147
1g	USD 670

Clinical Trials

Numerous clinical trials evaluate piperacillin across Phase 1 through Phase 4, alongside observational and pharmacokinetic studies, targeting conditions such as severe pneumonia, sepsis, septic shock, acute respiratory distress syndrome, and appendicitis. Sponsored by academic medical centers, university hospitals, and pharmaceutical entities, trial statuses range from completed Phase 3 and Phase 4 evaluations to actively recruiting studies investigating empirical sepsis management.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07759453	NOT_YET_RECRUITING	Liver Transplant; Carbapenem-resistant Enterobacterales; CRE Colonization	IRCCS Azienda Ospedaliero-Universitaria di Bologna	2026-10-01	PHASE3
NCT06954129	RECRUITING	Acute Kidney Injury	University of Pennsylvania	2026-01-28	PHASE4
NCT07620223	RECRUITING	Hepatobiliary Surgery; Prophylactic Antibiotics	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	2026-05-24
NCT06123169	NOT_YET_RECRUITING	Pancreaticoduodenectomy; Antibiotherapy	University Hospital, Rouen	2026-07	PHASE3
NCT06184659	RECRUITING	Sepsis; Septic Shock	Scandinavian Critical Care Trials Group	2025-06-26	PHASE4
NCT07556107	RECRUITING	Infection; Acute Kidney Injury; Sepsis	Bassett Healthcare	2026-08-17	PHASE4
NCT06712641	RECRUITING	Sepsis	University Hospital, Akershus	2026-04-23	PHASE4
NCT07484633	NOT_YET_RECRUITING	Infection; Sepsis; NICU; PICU; Beta Lactams	Semmelweis University	2026-04	PHASE4
NCT07481539	RECRUITING	Bacteria Infection; Piperacillin, Tazobactam Drug Combination	Azienda Sanitaria Universitaria Friuli Centrale	2026-03-24	PHASE2
NCT03078010	ACTIVE_NOT_RECRUITING	Intestinal Microbiome; Febrile Neutropenia	Memorial Sloan Kettering Cancer Center	2017-02-10	PHASE2
NCT03671967	RECRUITING	Beta Lactam Resistant Bacterial Infection; Enterobacteriaceae Infections; Bacteremia	Rambam Health Care Campus	2019-05-01	PHASE4
NCT06977347	NOT_YET_RECRUITING	Severe Community-acquired Pneumonia (sCAP)	CHOSEOK YOON	2025-06-15
NCT07352605	NOT_YET_RECRUITING	Diverticular Disease of Colon	Azienda Sanitaria di Firenze	2026-04
NCT06972537	RECRUITING	Pneumonia	Shandong University	2024-07-24
NCT06426836	RECRUITING	Pharmacokinetics; Amoxicillin-clavulanate; Piperacillin-tazobactam; Meropenem; Cefazolin; Teicoplanin; Vancomycin; Ciprofloxacin; Amikacin	University Hospital, Ghent	2016-08-19
NCT05565222	UNKNOWN	Sepsis; Septic Shock	Assistance Publique - Hôpitaux de Paris	2023-03-11	PHASE3
NCT06293677	UNKNOWN	Febrile Neutropenia	Centre Hospitalier Universitaire Vaudois	2024-03-01	PHASE4
NCT02735707	RECRUITING	Community-acquired Pneumonia, Influenza, COVID-19	UMC Utrecht	2016-04-11	PHASE3
NCT04948463	COMPLETED	Febrile Neutropenia	Murdoch Childrens Research Institute	2021-11-15	PHASE4
NCT06690905	COMPLETED	Infections; Obesity and Obesity-related Medical Conditions	CR-CSSS Champlain-Charles-Le Moyne	2025-02-26	PHASE4
NCT06422533	UNKNOWN	Hematologic Neoplasms; Neutropenia	Instituto Nacional de Cancerologia de Mexico	2023-11-07
NCT05355350	WITHDRAWN	Beta Lactam Resistant Bacterial Infection; Enterobacteriaceae Infections; Bacteremia	Rambam Health Care Campus	2022-07-01	PHASE4
NCT05943223	COMPLETED	Appendicitis Perforated	McMaster Children's Hospital	2024-09-09	PHASE2
NCT06026852	UNKNOWN	Infections	University Hospital, Ghent	2024-09-26
NCT03269994	COMPLETED	Pancreatic Cancer; Pancreas Cancer; Pancreatic Diseases	Memorial Sloan Kettering Cancer Center	2017-11-21	PHASE3
NCT05981079	UNKNOWN	Late-Onset Neonatal Sepsis	Shandong University	2023-07-31	PHASE4
NCT03891433	SUSPENDED	Urinary Tract Infections; Enterobacteriaceae Infections; Infection Due to ESBL Bacteria; Carbapenem; Escherichia Coli Infection; Klebsiella Pneumoniae Infection; Clinical Trial; Drug Resistance, Bacterial	Universidad del Norte	2019-04-01	PHASE4
NCT06338345	Not yet recruiting	Cardiogenic Shock\|Post-cardiac Surgery\|Cardiac Arrest\|Extracorporeal Membrane Oxygenation Complication\|Infections	University Hospital Grenoble	2024-09-01	Not Applicable
NCT04276480	COMPLETED	Enterobacteriaceae Infections	University Hospital, Bordeaux	2022-02-16
NCT05753735	TERMINATED	Pancreatic Fistula	Case Comprehensive Cancer Center	2024-01-18	PHASE2
NCT04983901	COMPLETED	Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm	M.D. Anderson Cancer Center	2021-09-14	PHASE2
NCT04816968	UNKNOWN	Severe Bacterial Infections	Ospedale San Carlo Borromeo	2021-09	PHASE1
NCT05608564	COMPLETED	Periodontitis	University of Belgrade	2023-01-17
NCT03262142	TERMINATED	COPD; Respiratory Tract Infections; Pseudomonas Aeruginosa; Bronchiectasis; Asthma	Chronic Obstructive Pulmonary Disease Trial Network, Denmark	2018-01-10	PHASE4
NCT05102162	TERMINATED	Pneumonia	University of Florida	2021-12-17	PHASE4
NCT03990467	UNKNOWN	Septic Shock; Sepsis; Sepsis Syndrome	Hospices Civils de Lyon	2021-01-28
NCT05464680	Recruiting	ARDS\|SARS-CoV 2 Pneumonia	Assistance Publique Hopitaux De Marseille	2022-11-24	Not Applicable
NCT05807217	Recruiting	Sepsis\|Acute Kidney Injury	Shen Ning\|Peking University Third Hospital	2022-10-26	--
NCT03583333	COMPLETED	Hospital-Acquired Bacterial Pneumonia; Ventilator-Associated Bacterial Pneumonia	Merck Sharp & Dohme LLC	2018-09-18	PHASE3
NCT05060419	UNKNOWN	Complicated Urinary Tract Infection; Acute Pyelonephritis	Qilu Pharmaceutical Co., Ltd.	2021-10-08	PHASE2
NCT04276480	Recruiting	Enterobacteriaceae Infections	University Hospital Bordeaux	2022-02-16	Not Applicable
NCT03862079	WITHDRAWN	Graft-versus-host Disease Prevention	M.D. Anderson Cancer Center	2020-06-01	PHASE2
NCT04233996	UNKNOWN	Febrile Neutropenia	Hospital Universitari de Bellvitge	2019-06-05	PHASE4
NCT03289351	COMPLETED	Perforated Appendicitis; Postoperative Infection	Phoenix Children's Hospital	2017-05-22	PHASE4
NCT03985514	COMPLETED	Appendicitis	Göteborg University	2018-05-15	PHASE4
NCT03485950	COMPLETED	Other Infectious Diseases	M.D. Anderson Cancer Center	2018-05-16	PHASE2
NCT02437045	COMPLETED	Bloodstream Infections	The University of Queensland	2015-04	PHASE4
NCT04394182	SUSPENDED	Pneumonia, Viral; Cytokine Storm	Fundacion GenesisCare	2020-04-21
NCT02991937	COMPLETED	Appendicitis	NYU Langone Health	2016-12	PHASE4
NCT04042077	TERMINATED	Surgical Site Infection	Menarini Group	2019-09-25	PHASE3
NCT03765645	COMPLETED	Antibiotic Prophylaxis; Postoperative Infection	Institute of Liver and Biliary Sciences, India	2018-10-04
NCT03006679	WITHDRAWN	Hospital-Acquired Bacterial Pneumonia; Ventilator-Associated Bacterial Pneumonia; Hospital-Acquired Pneumonia; Ventilator-Associated Pneumonia	Melinta Therapeutics, Inc.	2018-08	PHASE3
NCT03560232	TERMINATED	Open Fracture; Post-Op Wound Infection	Mercy Health Ohio	2018-07-09	PHASE4
NCT03687255	COMPLETED	Urinary Tract Infections	Allecra	2018-09-24	PHASE3
NCT04895657	COMPLETED	Gram-Negative Infections	Ain Shams University	2018-07-27	PHASE4
NCT03019965	COMPLETED	Sepsis	Coordinación de Investigación en Salud, Mexico	2017-02-01
NCT02493764	COMPLETED	Bacterial Pneumonia	Merck Sharp & Dohme LLC	2015-11-24	PHASE3
NCT02473263	COMPLETED	Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit	Assistance Publique - Hôpitaux de Paris	2016-05-09	PHASE3
NCT02466438	UNKNOWN	Infection	St. Justine's Hospital	2016-01	PHASE1
NCT02820987	COMPLETED	Septic Shock	Centre Hospitalier Universitaire de Besancon	2016-09-27	PHASE3
NCT03441529	COMPLETED	Healthy	Janssen Research & Development, LLC	2018-02-09	PHASE1
NCT03376529	COMPLETED	Healthy Volunteers	Spero Therapeutics	2017-11-10	PHASE1
NCT02619149	COMPLETED	Cholecystitis, Acute	Karolinska Institutet	2009-03	PHASE3
NCT02840136	TERMINATED	Cystic Fibrosis	University Ghent	2016-02
NCT02176122	TERMINATED	Bloodstream Infections	The University of Queensland	2014-02	PHASE4
NCT01667094	UNKNOWN	Cystic Fibrosis	The Alfred	2012-09	PHASE4
NCT02463747	UNKNOWN	Fever; Febrile Neutropenia	Tel-Aviv Sourasky Medical Center	2015-06	PHASE4
NCT02191475	UNKNOWN	Abdominal Infection	Tianjin Medical University Cancer Institute and Hospital	2014-05	PHASE2; PHASE3
NCT02817347	TERMINATED	Otitis Media; Otorrhea	Yuhan Corporation	2016-06	PHASE1; PHASE2
NCT01994993	COMPLETED	Complicated Intra Abdominal Infections	Michael Cohen-Wolkowiez	2013-12	PHASE2; PHASE3
NCT02753946	COMPLETED	Urinary Tract Infection Symptomatic; Acute Pyelonephritis; Urinary Tract Infection Complicated	Nabriva Therapeutics AG	2016-04	PHASE2; PHASE3
NCT01796717	UNKNOWN	Nosocomial Pneumonia	Tianjin Medical University Cancer Institute and Hospital	2012-03	PHASE2; PHASE3
NCT02732327	TERMINATED	Neoplasms; Febrile Neutropenia	Forest Laboratories	2016-05-17	PHASE2
NCT01760109	COMPLETED	Respiratory Tract Infections; Urinary Tract Infections	Xiangbei Welman Pharmaceutical Co., Ltd	2011-07	PHASE4
NCT02730624	COMPLETED	Early Phase of Severe Sepsis and Septic Shock	Sutep Jaruratanasirikul	2014-03	PHASE4
NCT02166476	COMPLETED	Urinary Tract Infection Complicated; Acute Pyelonephritis	Melinta Therapeutics, Inc.	2014-11-20	PHASE3
NCT01923363	COMPLETED	Obesity	Loma Linda University	2014-02-25
NCT01897831	UNKNOWN	Respiratory Tract Infections; Urinary Tract Infections	Xiangbei Welman Pharmaceutical Co., Ltd	2011-08	PHASE4
NCT01697059	COMPLETED	Acute Appendicitis	Rhode Island Hospital	2012-09
NCT01714557	UNKNOWN	Neutropenia; Hematopoietic Stem Cell Transplantation	Chinese PLA General Hospital	2012-09
NCT01714570	COMPLETED	Febrile; Neutropenia; Hematopoietic Stem Cell Transplantation	Chinese PLA General Hospital	2012-11
NCT03685084	COMPLETED	Healthy	Allecra	2013-10-10	PHASE1
NCT01577368	COMPLETED	Pseudomonas Aeruginosa Infection	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	2011-05	PHASE3
NCT01370616	COMPLETED	Infection; Diabetic Foot	Merck Sharp & Dohme LLC	2011-09-02	PHASE3
NCT01853982	TERMINATED	Ventilator-Associated Pneumonia (VAP)	Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	2013-06-14	PHASE3
NCT01694069	TERMINATED	Cystic Fibrosis	West Virginia University	2012-09	PHASE4
NCT01517815	COMPLETED	Septic Shock	University Hospital, Montpellier	2012-02
NCT01198925	COMPLETED	Infectious Disease	University Hospital, Ghent	2010-09-23	PHASE4
NCT00703144	COMPLETED	Diffusive and Convective Clearance; Body Clearance; Piperacillin Tazocilline Concentrations (Cmin)	University Hospital, Toulouse	2008-06	PHASE4
NCT01805856	COMPLETED	Thyroid Disease; Parathyroid Disease	Ito Hospital	2010-11
NCT00629135	COMPLETED	Abscess, Intra-Abdominal	Hannover Medical School	2005-11-15	PHASE3
NCT00816790	TERMINATED	Septic Shock; Acute Renal Failure	Fraser Health	2009-01	PHASE4
NCT01290003	COMPLETED	Neonatal Sepsis	Lady Hardinge Medical College	2010-06
NCT01027832	UNKNOWN	Tracheobronchitis	Assaf-Harofeh Medical Center	2009-09	PHASE2; PHASE3
NCT00873327	COMPLETED	Sepsis	Phillip Brian Smith	2009-10	PHASE1
NCT00894439	COMPLETED	Healthy Subjects	Wyeth is now a wholly owned subsidiary of Pfizer	2009-05	PHASE1
NCT00924742	COMPLETED	Healthy	Tri-Service General Hospital (TSGH)	2009-03
NCT00402727	COMPLETED	Abscess; Wound Infection; Diabetic Foot; Ulcer	Bayer	2006-09	PHASE3
NCT00253955	COMPLETED	Pneumonia	Sanofi	2003-06	PHASE3
NCT00389987	COMPLETED	Complicated Intra-Abdominal Infections	Merck Sharp & Dohme LLC	2001-09	PHASE3
NCT00229112	COMPLETED	Foot Infections in Diabetic Patients	Merck Sharp & Dohme LLC	2001-04	PHASE3
NCT00044928	COMPLETED	Bacterial Infections	Wyeth is now a wholly owned subsidiary of Pfizer	2002-07	PHASE4
NCT00044746	COMPLETED	Diabetes Mellitus; Diabetic Foot	Wyeth is now a wholly owned subsidiary of Pfizer	2000-10	PHASE4
NCT00003805	COMPLETED	Bone Marrow Suppression; Fever, Sweats, and Hot Flashes; Infection; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific	European Organisation for Research and Treatment of Cancer - EORTC	1997-11	PHASE3
NCT00153634	COMPLETED	Cystic Fibrosis; Chronic Bronchitis	Seattle Children's Hospital	2004-03
NCT00236912	TERMINATED	Appendicitis	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2003-07	PHASE4
NCT00438269	COMPLETED	Nosocomial Infection; Pneumonia; Systemic Inflammatory Response Syndrome; Critical Illness; Pyrexia	Canadian Critical Care Trials Group	2003-02	PHASE2
NCT00478855	COMPLETED	Bacterial Infections	Wyeth is now a wholly owned subsidiary of Pfizer	2006-09	PHASE4
NCT00044759	COMPLETED	Hematologic Neoplasms	Wyeth is now a wholly owned subsidiary of Pfizer		PHASE3

(data from https://clinicaltrials.gov, updated on 2026-08-12)

Check the Piperacillin Sodium product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Piperacillin functions by selectively binding to bacterial penicillin-binding proteins, which prevents essential transpeptidation reactions during peptidoglycan cell wall synthesis. This enzymatic inhibition causes cell wall structural weakness and subsequent osmotic cell lysis, leading to bacterial death in critical clinical conditions such as sepsis, severe pneumonia, and abdominal infections.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).